• Something wrong with this record ?

Human NR5A1/SF-1 mutations show decreased activity on BDNF (brain-derived neurotrophic factor), an important regulator of energy balance: testing impact of novel SF-1 mutations beyond steroidogenesis

J. Malikova, N. Camats, M. Fernández-Cancio, K. Heath, I. González, M. Caimarí, M. del Campo, M. Albisu, S. Kolouskova, L. Audí, CE. Flück,

. 2014 ; 9 (8) : e104838. [pub] 20140814

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

CONTEXT: Human NR5A1/SF-1 mutations cause 46,XY disorder of sex development (DSD) with broad phenotypic variability, and rarely cause adrenal insufficiency although SF-1 is an important transcription factor for many genes involved in steroidogenesis. In addition, the Sf-1 knockout mouse develops obesity with age. Obesity might be mediated through Sf-1 regulating activity of brain-derived neurotrophic factor (BDNF), an important regulator of energy balance in the ventromedial hypothalamus. OBJECTIVE: To characterize novel SF-1 gene variants in 4 families, clinical, genetic and functional studies were performed with respect to steroidogenesis and energy balance. PATIENTS: 5 patients with 46,XY DSD were found to harbor NR5A1/SF-1 mutations including 2 novel variations. One patient harboring a novel mutation also suffered from adrenal insufficiency. METHODS: SF-1 mutations were studied in cell systems (HEK293, JEG3) for impact on transcription of genes involved in steroidogenesis (CYP11A1, CYP17A1, HSD3B2) and in energy balance (BDNF). BDNF regulation by SF-1 was studied by promoter assays (JEG3). RESULTS: Two novel NR5A1/SF-1 mutations (Glu7Stop, His408Profs*159) were confirmed. Glu7Stop is the 4th reported SF-1 mutation causing DSD and adrenal insufficiency. In vitro studies revealed that transcription of the BDNF gene is regulated by SF-1, and that mutant SF-1 decreased BDNF promoter activation (similar to steroid enzyme promoters). However, clinical data from 16 subjects carrying SF-1 mutations showed normal birth weight and BMI. CONCLUSIONS: Glu7Stop and His408Profs*159 are novel SF-1 mutations identified in patients with 46,XY DSD and adrenal insufficiency (Glu7Stop). In vitro, SF-1 mutations affect not only steroidogenesis but also transcription of BDNF which is involved in energy balance. However, in contrast to mice, consequences on weight were not found in humans with SF-1 mutations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16021070
003      
CZ-PrNML
005      
20160722120233.0
007      
ta
008      
160722s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0104838 $2 doi
024    7_
$a 10.1371/journal.pone.0104838 $2 doi
035    __
$a (PubMed)25122490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malikova, Jana $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Pediatric Endocrinology, Department of Pediatrics and Department of Clinical Research, University Children's Hospital Bern, Bern, Switzerland.
245    10
$a Human NR5A1/SF-1 mutations show decreased activity on BDNF (brain-derived neurotrophic factor), an important regulator of energy balance: testing impact of novel SF-1 mutations beyond steroidogenesis / $c J. Malikova, N. Camats, M. Fernández-Cancio, K. Heath, I. González, M. Caimarí, M. del Campo, M. Albisu, S. Kolouskova, L. Audí, CE. Flück,
520    9_
$a CONTEXT: Human NR5A1/SF-1 mutations cause 46,XY disorder of sex development (DSD) with broad phenotypic variability, and rarely cause adrenal insufficiency although SF-1 is an important transcription factor for many genes involved in steroidogenesis. In addition, the Sf-1 knockout mouse develops obesity with age. Obesity might be mediated through Sf-1 regulating activity of brain-derived neurotrophic factor (BDNF), an important regulator of energy balance in the ventromedial hypothalamus. OBJECTIVE: To characterize novel SF-1 gene variants in 4 families, clinical, genetic and functional studies were performed with respect to steroidogenesis and energy balance. PATIENTS: 5 patients with 46,XY DSD were found to harbor NR5A1/SF-1 mutations including 2 novel variations. One patient harboring a novel mutation also suffered from adrenal insufficiency. METHODS: SF-1 mutations were studied in cell systems (HEK293, JEG3) for impact on transcription of genes involved in steroidogenesis (CYP11A1, CYP17A1, HSD3B2) and in energy balance (BDNF). BDNF regulation by SF-1 was studied by promoter assays (JEG3). RESULTS: Two novel NR5A1/SF-1 mutations (Glu7Stop, His408Profs*159) were confirmed. Glu7Stop is the 4th reported SF-1 mutation causing DSD and adrenal insufficiency. In vitro studies revealed that transcription of the BDNF gene is regulated by SF-1, and that mutant SF-1 decreased BDNF promoter activation (similar to steroid enzyme promoters). However, clinical data from 16 subjects carrying SF-1 mutations showed normal birth weight and BMI. CONCLUSIONS: Glu7Stop and His408Profs*159 are novel SF-1 mutations identified in patients with 46,XY DSD and adrenal insufficiency (Glu7Stop). In vitro, SF-1 mutations affect not only steroidogenesis but also transcription of BDNF which is involved in energy balance. However, in contrast to mice, consequences on weight were not found in humans with SF-1 mutations.
650    _2
$a mozkový neurotrofický faktor $x fyziologie $7 D019208
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a energetický metabolismus $x fyziologie $7 D004734
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a rodokmen $7 D010375
650    _2
$a steroidogenní faktor 1 $x genetika $7 D054339
650    _2
$a steroidy $x biosyntéza $7 D013256
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Camats, Núria $u Pediatric Endocrinology, Department of Pediatrics and Department of Clinical Research, University Children's Hospital Bern, Bern, Switzerland.
700    1_
$a Fernández-Cancio, Mónica $u Pediatric Endocrinology, Vall d'Hebron Research Institute VHIR, CIBERER, Autonomous University, Barcelona, Spain.
700    1_
$a Heath, Karen $u Institute of Medical and Molecular Genetics INGEMM, Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ, Madrid, Spain.
700    1_
$a González, Isabel $u Pediatric Endocrinology Service, Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ, Madrid, Spain.
700    1_
$a Caimarí, María $u Pediatric Endocrinology, Son Espases University Hospital, Palma de Mallorca, Spain.
700    1_
$a del Campo, Miguel $u Genetic Service, Hospital Vall d'Hebron, Barcelona, Spain.
700    1_
$a Albisu, Marian $u Pediatric Endocrinology, Vall d'Hebron Research Institute VHIR, CIBERER, Autonomous University, Barcelona, Spain. $7 gn_A_00003523
700    1_
$a Kolouskova, Stanislava $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Audí, Laura $u Pediatric Endocrinology, Vall d'Hebron Research Institute VHIR, CIBERER, Autonomous University, Barcelona, Spain. $7 gn_A_00009936
700    1_
$a Flück, Christa E $u Pediatric Endocrinology, Department of Pediatrics and Department of Clinical Research, University Children's Hospital Bern, Bern, Switzerland.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 8 (2014), s. e104838
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25122490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160722120447 $b ABA008
999    __
$a ok $b bmc $g 1155740 $s 945598
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 8 $d e104838 $e 20140814 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...